NO760162L - - Google Patents
Info
- Publication number
- NO760162L NO760162L NO760162A NO760162A NO760162L NO 760162 L NO760162 L NO 760162L NO 760162 A NO760162 A NO 760162A NO 760162 A NO760162 A NO 760162A NO 760162 L NO760162 L NO 760162L
- Authority
- NO
- Norway
- Prior art keywords
- tartar
- solution
- hydroxyapatite
- polyphosphate
- composition according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 claims description 18
- 150000001768 cations Chemical class 0.000 claims description 15
- 229920000388 Polyphosphate Polymers 0.000 claims description 14
- 239000001205 polyphosphate Substances 0.000 claims description 14
- 235000011176 polyphosphates Nutrition 0.000 claims description 14
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 claims description 6
- 235000019982 sodium hexametaphosphate Nutrition 0.000 claims description 6
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 claims description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 230000000737 periodic effect Effects 0.000 claims 1
- 208000006558 Dental Calculus Diseases 0.000 description 19
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 17
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 17
- 239000000243 solution Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 229910052500 inorganic mineral Inorganic materials 0.000 description 9
- 239000011707 mineral Substances 0.000 description 9
- 235000010755 mineral Nutrition 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000002845 discoloration Methods 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 210000003296 saliva Anatomy 0.000 description 5
- 239000000606 toothpaste Substances 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 229940005740 hexametaphosphate Drugs 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 230000001089 mineralizing effect Effects 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 229940034610 toothpaste Drugs 0.000 description 4
- OYPRJOBELJOOCE-BKFZFHPZSA-N Calcium-45 Chemical compound [45Ca] OYPRJOBELJOOCE-BKFZFHPZSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 230000033558 biomineral tissue development Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000013068 control sample Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 230000010736 Chelating Activity Effects 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- XIWMTQIUUWJNRP-UHFFFAOYSA-N amidol Chemical compound NC1=CC=C(O)C(N)=C1 XIWMTQIUUWJNRP-UHFFFAOYSA-N 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002272 anti-calculus Effects 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229910001451 bismuth ion Inorganic materials 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 239000005548 dental material Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Description
Foreliggende oppfinnelse vedrorer tannstensmotvirkende komposisjoner som består av polyfosfater med varierende kjedelengde og flerverdige metallkationer. Disse ionene kan kombineres i vannlosning og visse forhold og konsentrasjoner av kombinasjonene forhindrer avsetning av belegg og tannsten på tannmaterialet i munnhulen. The present invention relates to tartar-fighting compositions consisting of polyphosphates with varying chain length and polyvalent metal cations. These ions can be combined in water discharge and certain conditions and concentrations of the combinations prevent the deposition of plaque and tartar on the dental material in the oral cavity.
Oppfinnelsen vedrorer således tannstensforhindrende og mis-fargingsforhindrende (anticalculus, antistain) komposisjoner for anvendelse in vivo, som består av polyfosfater med varierende kjedelengde og flerverdige metallkationer. The invention thus relates to calculus-preventing and discolouration-preventing (anticalculus, antistain) compositions for use in vivo, which consist of polyphosphates with varying chain length and polyvalent metal cations.
For å kunne anvendes ifolge oppfinnelsen, må metallkationene kunne kombineres med polyfosfater i losning. Polyfosfåtene kan ha en lengde varierende fra pyrofosfat til polyfosfat-glass med mer enn 2o fosfatenheter i lengden. In order to be used according to the invention, the metal cations must be able to be combined with polyphosphates in solution. The polyphosphates can have a length varying from pyrophosphate to polyphosphate glass with more than 20 phosphate units in length.
Forekomst av tannsten i munnhulen er et problem som hoved-saklig er en plage for voksne. Dette fenomenet er slutt-resultatet av mineraliseringen av en organisk film som finnes på tannen og kalles plakk. Det mineralet som avsettes, er samme materiale som inngår i tennene, nemlig hydroksyapatitt. Denne mineraliserende filmen er noe mindre krystallinsk enn tannemalje og inneholder en organisk grunnmasse. Opptreden av tannsten kan medfore både kosmetiske og medisinske vanskeligheter. Tannsten blir ofte misfarget ved dannelsen, hvilket innvirker ufordelaktig på individets utseende. Også tenner hos visse< dyr oppviser tannsten og misfarging og kan kreve behandling. The occurrence of tartar in the oral cavity is a problem which is mainly a nuisance for adults. This phenomenon is the end result of the mineralization of an organic film found on the tooth called plaque. The mineral that is deposited is the same material that is part of the teeth, namely hydroxyapatite. This mineralizing film is somewhat less crystalline than tooth enamel and contains an organic ground mass. The appearance of tartar can cause both cosmetic and medical difficulties. The tartar often becomes discolored during formation, which has an unfavorable effect on the individual's appearance. Teeth in certain animals also show tartar and discoloration and may require treatment.
Dessuten virker tannsten ofte irriterende på tannkjottet ogIn addition, tartar often irritates the gums and
kan forårsake betennelse, smerte, blodning, bakterieinvasjoncan cause inflammation, pain, bleeding, bacterial invasion
og tannkjottstilbaketrekning ved dannelse ved eller under tann-kjottslinjen. Det endelige resultatet er periodontitt med medfolgende benresorpsjon og tanntap. Således mister voksne flere tenner på grunn av periodontitt enn av noen annen grunn, og tannsten anses for å være en vesentlig medvirkende faktor. and gingival retraction when forming at or below the gingival line. The final result is periodontitis with accompanying bone resorption and tooth loss. Thus, adults lose more teeth due to periodontitis than for any other reason, and tartar is considered to be a significant contributing factor.
Hittil har tannsten kunnet reguleres ved to metoder, (1) meka-nisk fjerning og (2) kjemisk hindring eller fjerning. Den forstnevnte metoden er ubehagelig og krever medvirkning av en utdannet fagmann. Den andre metoden medforer risiko for tap av tannmineral ettersom mineralbestanddelen i tennene og tannsten er den samme. Man har hittil ikke kunnet finne noen kjemisk forbindelse som fjerner tannsten og ikke tannmineral. Det beste resultatet man har kunnet oppnå på dette området har således vært å forhindre eller forsinket dannelsen av tannsten. Until now, calculus has been able to be controlled by two methods, (1) mechanical removal and (2) chemical obstruction or removal. The former method is uncomfortable and requires the involvement of a trained professional. The second method entails a risk of loss of tooth mineral as the mineral component of the teeth and tartar is the same. So far, no chemical compound has been found that removes tartar and not tooth mineral. The best result that has been achieved in this area has thus been to prevent or delay the formation of tartar.
Foruten den misfarging av tennene som er forbundet med tannsten, kan misfarging opptre på overflaten av tenner uten å være forbundet med tannsten. Denne misfargingen er alltid meget vanskelig å fjerne og forårsaker alvorlige kosmetiske problemer. Hittil har disse misfargingene kunnet fjernes effektivt bare gjennom en profylaktisk rengjoring. Det har helt overraskende vist seg at daglig anvendelse av en komposisjon som inntas oralt og inneholder magnesiumklorid samt natriumheksametafosfat i varierende mengder i vesentlig grad minsker misfarging.som er forårsaket av tobakk, te, kaffe og næringsmidler. In addition to the discoloration of the teeth associated with calculus, discoloration can appear on the surface of teeth that is not associated with calculus. This discoloration is always very difficult to remove and causes serious cosmetic problems. Until now, these discolourations could only be removed effectively through a prophylactic cleaning. Surprisingly, it has been shown that daily use of a composition which is taken orally and contains magnesium chloride and sodium hexametaphosphate in varying amounts significantly reduces discoloration caused by tobacco, tea, coffee and foodstuffs.
Komposisjonen ifolge oppfinnelsen består av polyfosfat og flerverdig kation. Ved anvendelse for skylling av munnen foreligger disse to bestanddelene i vannlosning, sammen med andre munnvanns-bestanddeler. Ved innarbeiding i tannkrem foreligger de to hovedbestanddelene i mer konsentrert form i en pasta som inneholder komponenter som typisk inngår i tannkrem. Tannkremskomposisjoner og lignende samt munnvanns-komposisjoner er angitt i tabell 1. Selv om et flertall flerverdige metallkationer har vist seg aktive i disse komposi- The composition according to the invention consists of polyphosphate and multivalent cation. When used for rinsing the mouth, these two components are present in water solution, together with other mouthwash components. When incorporated into toothpaste, the two main ingredients are present in a more concentrated form in a paste that contains components that are typically included in toothpaste. Toothpaste compositions and the like as well as mouthwash compositions are listed in Table 1. Although a majority of polyvalent metal cations have been shown to be active in these compositions
!sjonene, er magnesium det kation som kan kombineres best med !tions, magnesium is the cation that can be combined best with
loselige polyfosfater og blokkerer kelatdannelses-aktiviteten mot kalsium. soluble polyphosphates and blocks the chelating activity against calcium.
Graden av kombinerbarhet for forskjellige flerverdige metallkationer i vannlosning med natriumheksametafosfat angis i tabell 2, som angir det approksimative antall mol kationer som gir fullstendig loselighet med polyfosfater ved romtempe-ratur. The degree of combinability for various polyvalent metal cations in aqueous solution with sodium hexametaphosphate is given in Table 2, which indicates the approximate number of moles of cations which give complete solubility with polyphosphates at room temperature.
Disse flerverdige kationer er kombinerbare med minst o,ol64 These polyvalent cations are combinable with at least o,ol64
mol pr. liter (1%'ig losning) og ved et molforhold på 1:1moles per liter (1% solution) and at a molar ratio of 1:1
eller bedre. Blant ioner som ikke er kombinerbare med dette innholdet er. sinkion, tinnion og vismution. or better. Among ions that are not combinable with this content are. zinc ion, tinnion and bismuthion.
Det polyfosfatet som er best egnet for dette formål er natriumheksametafosfat, selv om kjedelengder som varierer fra pyrofosfater til glasser med mer enn 2o fosfatenheter også The polyphosphate most suitable for this purpose is sodium hexametaphosphate, although chain lengths varying from pyrophosphates to glasses with more than 2o phosphate units also
viser aktivitet.shows activity.
Den mekanisme hvorigjennom disse komposisjoner inhiberer eller forsinker tannstensdannelsen er ennå ikke helt klarlagt, men det er mulig å forutsi en mekanisme. Tilgjengelige fakta antyder at polyfosfatkjedene bindes til overflaten av hydroksy-apatittmikrokrystaller som dannes i plakk og til tannoverflaten selv. Krystallene forhindres i å vokse ytterligere gjennom denne dannelsen, hvilket forsinker mineralisering av plakk, The mechanism by which these compositions inhibit or delay tartar formation is not yet fully understood, but it is possible to predict a mechanism. Available evidence suggests that the polyphosphate chains bind to the surface of hydroxyapatite microcrystals that form in plaque and to the tooth surface itself. The crystals are prevented from growing further through this formation, delaying the mineralization of plaque,
som herved kan borstes bort. Når mineraliseringen blir fullstendig kan den tannsten som dannes ikke lenger borstes bort og må fjernes av en utdannet fagmann. Selv om tannsten som allerede forefinnes i munnen, tiltar langsommere ved anvendelse av which can thereby be brushed away. When the mineralization becomes complete, the tartar that forms can no longer be brushed away and must be removed by a trained professional. Although tartar that is already present in the mouth increases more slowly with the use of
et produkt ifolge oppfinnelsen, kommer derfor maksimalt utbytte til å erholdes om man foretar dental profylakse for anvendelse av produktene. a product according to the invention, maximum benefit will therefore be obtained if dental prophylaxis is carried out for use of the products.
Fakta antyder at negativt ladede flerverdige anioner, eksempel-vis karboksymetylcellulose og organiske polymerer som inneholder difosfonatbindinger, også absorberes til hydroksyapatitt. imidlertid absorberes disse polymerene ikke like sterkt som polyfosfater eller også er de potensielt giftige. The facts suggest that negatively charged polyvalent anions, for example carboxymethylcellulose and organic polymers containing diphosphonate linkages, are also absorbed into hydroxyapatite. however, these polymers are not absorbed as strongly as polyphosphates or are potentially toxic.
Oppfinnelsens virkning kan demonstreres både in vitro ogThe effect of the invention can be demonstrated both in vitro and
in vivo. In vitro-metoden for å vise virkningen i forhold til hydroksyapatitt ifolge oppfinnelsen er å måle effekten av en proveforbindelse på syreloseligheten av pulverformig hydroksyapatitt eller på en ekstrahert, hel tannoverflate. Metoden er som folger: 5o mg pulverformig hydroksyapatitt (HAP) utsettes lo minutter for påvirkning av lo ml av en vannlosning, hvori var opplost eller suspendert det materialet som skulle proves. Proven ble sentrifugert og den fraskilte væsken ble kastet. HAP in vivo. The in vitro method for showing the effect in relation to hydroxyapatite according to the invention is to measure the effect of a test compound on the acid solubility of powdered hydroxyapatite or on an extracted, whole tooth surface. The method is as follows: 5o mg of powdered hydroxyapatite (HAP) is exposed for 10 minutes to the influence of 10 ml of a water solution, in which the material to be tested was dissolved or suspended. The sample was centrifuged and the separated liquid was discarded. HOPE
ble vasket to ganger med vann og deretter utsatt for påvirkning av eddiksyre (pH =3) i lo minutter. Uppslemmingen ble filtrert og filterkaken inneholdt ikke-opplost HAP. Som kontrollprove ble også 5o mg HAP, som ble forbehandlet med vann, utsatt for påvirkning av eddiksyre (pH =3) i lo minutter og filtrert. Samtlige filtrater ble analysert med hensyn til opplost fosfat ifolge Fiske-Subarrow-metoden på folgende måte: Et,provevolum på o,2 ml av filtratet ble tilsatt 4,8 ml o,5N ^SO^ etterfulgt o,7 ml molybdat-sulfatlosning (3,o g ammoniummolybdat, 9o ml H2O, 16 ml kons. H^SO^) og o,3 ml reduksjonsmiddel (l,o% 2,4-diaminofenol i lo% NaHS03). Etter 5 minutter måles den erholdte fargen spektrometrisk for bestemmelse av mengde fosfat som ble loseliggjort av syren. was washed twice with water and then exposed to the action of acetic acid (pH =3) for lo minutes. The slurry was filtered and the filter cake contained undissolved HAP. As a control sample, 50 mg of HAP, which was pre-treated with water, was also exposed to the influence of acetic acid (pH =3) for 10 minutes and filtered. All filtrates were analyzed for dissolved phosphate according to the Fiske-Subarrow method in the following way: A sample volume of o.2 ml of the filtrate was added to 4.8 ml of o.5N ^SO^ followed by o.7 ml of molybdate-sulphate solution ( 3.o g ammonium molybdate, 9o ml H2O, 16 ml conc. H^SO^) and o.3 ml reducing agent (1.0% 2,4-diaminophenol in lo% NaHS03). After 5 minutes, the color obtained is measured spectrometrically to determine the amount of phosphate that was loosened by the acid.
Den prosentuelle' nedsettelsen av syreloseligheten ble bestemt med en referanse til kontrollproven. Visse av de oppnådde resultater er angitt i tabell 1. Forsøksresultatene oppnås •' også ved anvendelse av ekstraherte mennesketenner i stedet for pulverformig HAP. Metoden for bestemmelse av syreloseligheten til tennene var vesentlig samme som for det pulverformige HAP. The percentage reduction in acid solubility was determined with reference to the control sample. Some of the results obtained are indicated in table 1. The experimental results are also obtained by using extracted human teeth instead of powdered HAP. The method for determining the acid insolubility of the teeth was essentially the same as for the powdered HAP.
Resultatene av disse undersøkelsene er angitt i tabell 3. The results of these investigations are shown in table 3.
Den i den foregående angitte proving viser forekomsten av heksametafosfatkompleksene ved å måle en reduksjon av syreloseligheten hos hydroksyapatittene. En mer direkte metode The previously indicated testing shows the presence of the hexametaphosphate complexes by measuring a reduction in the acid solubility of the hydroxyapatites. A more direct method
for vurdering av forbindelser med hensyn til tannstensmotvirkende effekt omfatter forbehandling av en film fremstilt av spytt som mineraliserer i det som betegnes "tannstensdannende losning". En provet forbindelse anvendes for forbehandling av spyttfilmen, og den mineralmengden som dannes sammenlignet med en film som forbehandles med vann er et mål for virkningen. for the evaluation of compounds with regard to anti-tartar effect includes pre-treatment of a film made from saliva which mineralizes in what is termed "tartar-forming solution". A proven compound is used for pre-treatment of the saliva film, and the amount of minerals formed compared to a film pre-treated with water is a measure of the effect.
Fblgende fremgangsmåte anvendes:The following procedure is used:
Filmer fremstilles av spytt med mineraliserende virkning gjennom utspredning av sentrifugert spyttvæske (supernatant) på en glasskive og torking gjennom påblåsing av luft. Disse torkede spyttfilmene forbehandles med den provede forbindelsen i 15 - 3o sekunder og innfores deretter i en tannstensdannende losning. Denne losningen inneholder de uorganiske ioner som forefinnes i ekstracellulær væske. Innholdene av kalsium og Films are produced from saliva with a mineralizing effect by spreading centrifuged saliva fluid (supernatant) on a glass disc and drying by blowing air. These dried saliva films are pretreated with the tested compound for 15-30 seconds and then introduced into a calculus-forming solution. This solution contains the inorganic ions found in extracellular fluid. The contents of calcium and
fosfor (som fosfat) justeres til 12 mg % respektive 5 mg %. pH-verdien hos losningen justeres til 7,25 og de forbehandlede phosphorus (as phosphate) is adjusted to 12 mg% and 5 mg% respectively. The pH value of the solution is adjusted to 7.25 and the pretreated
glassplatene innfores i den mineraliserende losningen og inku-beres ved 37°C. 24 timer senere fjernes glassplatene fra den mineraliserende losningen og det dannede mineralet opploses i 5 ml o,5N H^SO^. Mengden uorganisk fosfat bestemmes ved the glass plates are introduced into the mineralizing solution and incubated at 37°C. 24 hours later, the glass plates are removed from the mineralizing solution and the formed mineral is dissolved in 5 ml o.5N H^SO^. The amount of inorganic phosphate is determined by
Fiske-Subarrow-metoden, som beskrevet i det foregående, og anvendes således som et mål for mengden mineral som dannes ved behandling av spyttfilmene. The Fiske-Subarrow method, as described above, and is thus used as a measure of the amount of mineral formed during treatment of the salivary films.
Resultatet i tabell 4 viser at samtlige flerverdige kationer reduserer mineraldannelsen. The results in table 4 show that all multivalent cations reduce mineral formation.
Til slutt vurderes de i det foregående angitte komposisjoners sikkerhet vedrorende opplosning av hydroksyapatittmineral sammen med 3 ledende kommersielle tannkremer (provene 14 - 16) ved anvendelse av kalsium-45-markert hydroksyapatitt. Folgende fremstillingsmåte anvendes: 2o mg med. kalsium-45-markert hydroksyapatitt suspenderes i 2o ml av provelosningen under omroring. Etter 1 minutts påvirkning filtreres suspen-sjonen umiddelbart. All væske som passerer filteret gjennom 1 minutt oppsamles og provemengder med volum o,2 ml tas ut for scintillasjonsmåling. Mengdene kalsium-45 i losningen anvendes som et mål for mengden opplost hydroksyapatitt. Finally, the safety of the aforementioned compositions regarding the dissolution of hydroxyapatite mineral is evaluated together with 3 leading commercial toothpastes (samples 14 - 16) using calcium-45-labeled hydroxyapatite. The following method of preparation is used: 2o mg med. calcium-45-labeled hydroxyapatite is suspended in 20 ml of the sample solution while stirring. After 1 minute of exposure, the suspension is filtered immediately. All liquid that passes the filter during 1 minute is collected and sample quantities with a volume of o.2 ml are taken out for scintillation measurement. The amounts of calcium-45 in the solution are used as a measure of the amount of dissolved hydroxyapatite.
De i tabell 5 angitte resultatene viser at nærværet av magnesium, kalsium og strontium i hoy grad reduserer den opplosende inn-virkningen på hydroksyapatitt av natriumheksametafosfat. Resultatene med konkurrerende produkter viser at mengden hydroksyapatitt som opploses av heksametafosfatmagnesium-kompleks'er sammenlignbar med den mengden som opploses av produkter som selges i handelen som tannkrem. Resultatene viser også at andre flerverdige metallkationer ikke er like effektive for å ^forhindre kelatbinding av kalsium. Kalsium minsker imidlertid aktiviteten av heksametafosfat for å forhindre krystalltilvekst og således tannstensdannelse. Magnesiumheksametafosfatkomplekset viste seg også å være virksomt in vivo. En losning som inneholdt 2% natriumheksametafosfat og 2% MgCl26H20 inhiberte i signifikant grad tilveksten av tannsten på tennene hos laboratorierotter. Samme komposisjon ble provet på mennesker og gav vesentlig redusert til-vekst av tannsten samt reduserte virksomt utvikling av misfarging. The results given in Table 5 show that the presence of magnesium, calcium and strontium greatly reduces the dissolving effect on hydroxyapatite of sodium hexametaphosphate. The results with competing products show that the amount of hydroxyapatite dissolved by hexametaphosphate magnesium complex is comparable to the amount dissolved by products sold commercially as toothpaste. The results also show that other polyvalent metal cations are not as effective in preventing chelate binding of calcium. However, calcium reduces the activity of hexametaphosphate to prevent crystal growth and thus tartar formation. The magnesium hexametaphosphate complex was also shown to be active in vivo. A solution containing 2% sodium hexametaphosphate and 2% MgCl26H20 significantly inhibited the growth of tartar on the teeth of laboratory rats. The same composition was tested on humans and significantly reduced the growth of tartar and effectively reduced the development of discoloration.
Det er åpenbart at forskjellige detaljer ved komposisjonene, f.eks. de bæremidler, som anvendes i komposisjoner ifolge oppfinnelsen, kan modifiseres uten at man avviker fra tanken ved oppfinnelsen, og at oppfinnelsen ikke er begrenset i dette henseende. It is obvious that various details of the compositions, e.g. the carriers used in compositions according to the invention can be modified without deviating from the idea of the invention, and that the invention is not limited in this respect.
Claims (5)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54201175A | 1975-01-17 | 1975-01-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO760162L true NO760162L (en) | 1976-07-20 |
Family
ID=24161988
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO760162A NO760162L (en) | 1975-01-17 | 1976-01-19 |
Country Status (7)
Country | Link |
---|---|
BE (1) | BE837701A (en) |
DK (1) | DK18776A (en) |
FR (1) | FR2297631A1 (en) |
NL (1) | NL7600503A (en) |
NO (1) | NO760162L (en) |
SE (1) | SE7600504L (en) |
ZA (1) | ZA76272B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1226525A (en) * | 1977-06-23 | 1987-09-08 | Gunnar Rolla | Lanthanum cation for cleaning teeth |
JPH0791177B2 (en) * | 1986-07-24 | 1995-10-04 | ライオン株式会社 | Oral composition for preventing tartar |
US5296217A (en) * | 1992-06-15 | 1994-03-22 | Indiana University Foundation | Methods for preventing dental calculus in domestic animals |
US6713049B1 (en) | 1999-11-12 | 2004-03-30 | The Procter & Gamble Company | Oral compositions providing optimal surface conditioning |
EP1227789B1 (en) | 1999-11-12 | 2004-09-22 | The Procter & Gamble Company | Improved dual phase stannous oral compositions |
US10470985B2 (en) | 1999-11-12 | 2019-11-12 | The Procter & Gamble Company | Method of protecting teeth against erosion |
US20040146466A1 (en) | 1999-11-12 | 2004-07-29 | The Procter & Gamble Company | Method of protecting teeth against erosion |
MXPA02004787A (en) | 1999-11-12 | 2002-08-30 | Procter & Gamble | Improved stannous oral compositions. |
US10123953B2 (en) | 2012-06-21 | 2018-11-13 | The Procter & Gamble Company | Reduction of tooth staining derived from cationic antimicrobials |
EP3958983A1 (en) | 2019-04-26 | 2022-03-02 | The Procter & Gamble Company | Reduction of tooth staining derived from cationic antimicrobials |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA721351B (en) * | 1971-03-22 | 1973-10-31 | Colgate Palmolive Co | Stable dentifrice |
-
1976
- 1976-01-19 DK DK18776*#A patent/DK18776A/en not_active Application Discontinuation
- 1976-01-19 NO NO760162A patent/NO760162L/no unknown
- 1976-01-19 ZA ZA760272A patent/ZA76272B/en unknown
- 1976-01-19 NL NL7600503A patent/NL7600503A/en not_active Application Discontinuation
- 1976-01-19 SE SE7600504A patent/SE7600504L/en unknown
- 1976-01-19 FR FR7601302A patent/FR2297631A1/en active Granted
- 1976-01-19 BE BE163624A patent/BE837701A/en unknown
Also Published As
Publication number | Publication date |
---|---|
NL7600503A (en) | 1976-07-20 |
ZA76272B (en) | 1977-03-30 |
FR2297631A1 (en) | 1976-08-13 |
SE7600504L (en) | 1976-07-18 |
FR2297631B1 (en) | 1979-06-29 |
BE837701A (en) | 1976-07-19 |
DK18776A (en) | 1976-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4556561A (en) | Compositions and methods for topically fluoridating and/or mineralizing dental tissue | |
US5437857A (en) | Methods and compositions for mineralizing and fluoridating calcified tissues | |
Lussi et al. | Fluorides—mode of action and recommendations for use | |
US5045305A (en) | Oral hygiene composition | |
EP0006708B1 (en) | Composition for controlling dental plaque and calculus | |
KR20140143757A (en) | Multicomponent oral care composition | |
DK163207B (en) | ORAL CARE, DENTAL DISPENSES CONTAINING THE PREPARATION AND PROCEDURE TO REDUCE OR PREVENT THE INACTIVATION OF A WATER SOLUBLE FLUORIDE SOURCE | |
JPH10511956A (en) | Control of calcium fluoride formation in gargles, toothpastes and gels | |
NO760162L (en) | ||
Gilbert et al. | The oral disposition of zinc following the use of an anticalculus toothpaste containing 0.5% zinc citrate | |
Baig et al. | Protective effects of S n F 2–Part I. Mineral solubilisation studies on powdered apatite | |
CA2626140A1 (en) | Fluoride-calcium compositions, dental products, and methods for providing dental fluoride | |
CA2953418C (en) | Anti-calculus oral compositions | |
EP0129201A2 (en) | Oral hygiene compositions | |
WO1994024991A1 (en) | Method of making a tartar control baking soda dentifrice | |
US3666855A (en) | Oral compositions and methods for retarding dental caries and calculus | |
Murata et al. | Fluoridation of hydroxyapatite powder by ammonium hexafluorosilicate | |
WO2018224331A1 (en) | Oral care composition | |
JPH0134966B2 (en) | ||
DE2602981A1 (en) | Dental prophylactic compsn. - contg. polyphosphate(s) and polyvalent cation | |
EP0428492B1 (en) | Improvement in the fluoride stability in dicalcium phosphate dihydrate composition | |
JPS6257164B2 (en) | ||
JP2738021B2 (en) | Toothpaste composition | |
JPH01163127A (en) | Composition for healing hyperesthesia | |
NO165897B (en) | PROGRAMMABLE CLUTCH CLOCK. |